Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

As weight loss medications like Ozempic and Wegovy become increasingly popular, questions arise about whether the nation is approaching pea ...

Goldman has a buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. The ...

Medicare covers sleep tests if you experience clinical signs and symptoms of sleep apnea, narcolepsy, or parasomnia. But there are some limitations depending on what condition is being screened for.

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release ... Mounjaro for T2D and Zepbound for obesity, which competes with NVO’s Ozempic and Wegovy.

Those on Medicare aren't exempt from this. Original Medicare's cost and coverage change annually. This affects how much you pay and the type of supplementary insurance you may want. Ideally ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.